Virtus Investment Advisers, Inc. Stoke Therapeutics, Inc. Transaction History
Virtus Investment Advisers, Inc.
- $286 Million
- Q2 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 7,955 shares of STOK stock, worth $275,640. This represents 0.03% of its overall portfolio holdings.
Number of Shares
7,955
Previous 13,323
40.29%
Holding current value
$275,640
Previous $88,000
2.27%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding STOK
# of Institutions
140Shares Held
58MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$187 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$187 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$178 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$161 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$152 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.37B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...